Zoetis Inc. (NYSE:ZTS) entered 2026 as a leader in animal health, but its latest earnings show that even a strong market position cannot fully insulate the company from weaker consumer demand. Fiscal Q2 2026 revenue remained flat at $2.5 billion and declined 1% on an organic operational basis, as pressure in the U.S. companion-animal market offset growth in livestock and international markets.
The quarter therefore presents investors with two different versions of Zoetis (NYSE:ZTS), as an established companion-animal business facing near-term pressure and a diversified animal-health platform still investing in its next generation of products.
Bull Case
Zoetis’s (NYSE:ZTS) diversification provided an important source of resilience during the quarter. Livestock revenue increased 12% on a reported basis, supported by cattle and poultry products. In the United States, livestock sales grew 23% on both a reported and organic operational basis in the quarter, benefiting from favorable beef-cattle economics, supply timing, and increased poultry-vaccine sales associated with disease outbreaks.
International performance was also encouraging. Revenue outside the United States rose 8% on a reported basis and 6% organically to $1.2 billion. International companion-animal sales grew 5% organically, supported by parasiticides such as Simparica Trio, Revolution and Stronghold, as well as diagnostics and newer osteoarthritis treatments. This geographic contrast demonstrates that the weakness was not uniform across Zoetis’s (NYSE:ZTS) business. Demand for its products remains healthy in several markets, even as U.S. pet owners become more price-sensitive.
However, innovation could provide another route back to growth, as Zoetis (NYSE:ZTS) says that its pipeline contains more than 12 potential blockbuster candidates across chronic kidney disease, oncology, cardiology, anxiety, and obesity. The company also launched Lenivia and Portela, long-acting osteoarthritis treatments offering dogs and cats up to three months of pain relief from one injection.
Zoetis (NYSE:ZTS) is expanding beyond medicines as well. Its acquisition of VitalRADS adds a veterinary teleradiology platform to its diagnostics business, potentially broadening the company’s role in veterinary care and creating an additional source of longer-term growth.
Bear Case
The most significant concern is the deterioration of Zoetis’s (NYSE:ZTS) core U.S. companion-animal business. U.S. segment revenue declined 7%, while companion-animal product sales fell 11%. Management attributed the weakness to lower veterinary-clinic visits, pet-owner price sensitivity, and intensified competition. Several important franchises were also affected. Zoetis (NYSE:ZTS) reported pressure on its dermatology portfolio and Simparica Trio, generic competition for Cerenia and Convenia, and lower Librela sales. This combination suggests the slowdown extends beyond a single product and reflects both economic and competitive challenges.
The reduction in full-year guidance makes the risks more difficult to dismiss as temporary quarterly volatility. Zoetis (NYSE:ZTS) lowered its 2026 revenue forecast from $9.68–$9.96 billion to $9.12–$9.32 billion. It now expects organic operational revenue to decline between 1% and 3%, compared with its previous expectation of 2%–5% growth.
Adjusted diluted EPS guidance was also cut from $6.85–$7.00 to $6.15–$6.25, while projected organic adjusted net-income growth moved from positive 2%–6% to a decline of 5%–9%. The scale of these revisions indicates that management expects the pressure to persist beyond one quarter.
Conclusion
Zoetis (NYSE:ZTS) still possesses valuable advantages, which include a diversified animal-health portfolio, international reach, and a pipeline targeting several potentially significant markets. Livestock and international growth demonstrate that important parts of the business remain healthy.
Nevertheless, the investment case shows some near-term headwinds. Declining U.S. companion-animal sales and substantially reduced guidance show that Zoetis (NYSE:ZTS) must adapt to softer demand while defending key franchises from competition. Its pipeline offers credible long-term potential, but investors will need evidence that new products can restore growth before treating the latest weakness as a temporary setback.
